KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) Equity Ratio (2016 - 2025)

Charles River Laboratories International has reported Equity Ratio over the past 17 years, most recently at 0.44 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.44 for Q4 2025, down 3.38% from a year ago — trailing twelve months through Dec 2025 was 0.44 (down 3.38% YoY), and the annual figure for FY2025 was 0.44, down 3.38%.
  • Equity Ratio for Q4 2025 was 0.44 at Charles River Laboratories International, down from 0.45 in the prior quarter.
  • Over the last five years, Equity Ratio for CRL hit a ceiling of 0.47 in Q3 2024 and a floor of 0.34 in Q3 2021.
  • Median Equity Ratio over the past 5 years was 0.42 (2023), compared with a mean of 0.41.
  • Biggest five-year swings in Equity Ratio: dropped 6.3% in 2021 and later increased 22.05% in 2023.
  • Charles River Laboratories International's Equity Ratio stood at 0.36 in 2021, then grew by 8.48% to 0.39 in 2022, then rose by 12.11% to 0.44 in 2023, then grew by 4.6% to 0.46 in 2024, then fell by 3.38% to 0.44 in 2025.
  • The last three reported values for Equity Ratio were 0.44 (Q4 2025), 0.45 (Q3 2025), and 0.44 (Q2 2025) per Business Quant data.